How is Doximity Expanding AI Partnerships?

Doximity is increasing spending on artificial intelligence in fiscal year 2027 as the company pushes deeper into physician workflow software, clinical AI search, and ambient documentation tools.

The company outlined the strategy during its fourth-quarter and full-year fiscal 2026 earnings call, where co-founder and CEO Jeff Tangney described 2026 as an “AI investment year” focused on scaling Doximity’s AI products for doctors. According to the company, investments will include higher research and development spending, compute infrastructure, AI review systems, and marketing for its clinical AI suite, which includes Ask and Scribe. The company’s fiscal 2027 began April 1.

Doximity said it plans to expand monetization of its AI-powered search tools for pharmaceutical marketers while continuing to grow physician adoption across hospitals and clinics. The company said more than 250,000 prescribers now have access to its clinical AI suite through hospital-approved workflows.

The company is also expanding distribution through a partnership with Aledade, which works with more than 3,000 primary care organizations participating in value-based care programs. Doximity will integrate its ambient documentation tool Scribe and AI assistant Ask into Aledade Assist, the company’s electronic health record overlay platform.

The move adds to growing adoption of AI-powered physician documentation systems across U.S. health systems, where hospitals are increasingly deploying ambient listening and workflow automation tools to reduce administrative workload for clinicians. Recent deployments have included systems such as UI Health’s rollout of Abridge AI tools and WellSpan Health’s implementation of Nuance DAX Copilot.

AI Workflow Expansion Drives Doximity Strategy

Doximity is also partnering with Photon Health to add in-workflow e-prescribing capabilities to its platform. The company said more than 1,000 prescribers participated in the beta rollout.

Executives said physician engagement with Doximity’s AI tools increased sharply over the past year. According to Tangney, active users of the company’s AI scribe and search tools tripled following Doximity’s acquisition of clinical AI company Pathway Medical in 2025.

The company acquired Pathway for $63 million last year to strengthen its evidence-based clinical AI search capabilities.

Doximity said nearly half of all U.S. doctors now work at hospitals that use its workflow or scheduling tools. The company also reported more than 800,000 quarterly active prescribers using its workflow products in the fourth quarter, up roughly 30% year over year.

The company is positioning physician review and clinical verification as a differentiator in the crowded healthcare AI market. Its PeerCheck system embeds physician review into AI-generated responses using a network of more than 10,000 medical experts.

Healthcare companies are increasingly competing to build AI systems that integrate directly into clinical workflows instead of functioning as standalone chatbots or search tools. That shift has also driven investment into AI agents, clinical assistants, and workflow automation platforms across healthcare operations, including companies focused on care coordination and administrative processes.

Investors React to Higher AI Spending and Lower Guidance

Despite the company’s AI growth metrics, investors reacted negatively to Doximity’s fiscal 2027 guidance. Shares of the company fell after earnings as Doximity projected full-year revenue between $664 million and $676 million, below Wall Street expectations near $697 million.

The company reported fiscal 2026 revenue of $644.9 million, up 13% year over year, while net income declined to $196.1 million from $223.2 million a year earlier.

Executives also warned that pharmaceutical marketing budgets remain under pressure due to regulatory uncertainty and macroeconomic conditions.

Doximity is simultaneously navigating increasing competition in clinical AI search and reference tools. The company competes with legacy clinical reference platforms such as UpToDate as well as newer AI-native companies including OpenEvidence.

The two companies are currently involved in ongoing federal litigation tied to allegations around AI platform access and competitive practices.